Document is current
Any future updates will be listed below
-
Authors
Zhou, Cathy
Yuan, Zilong
Ma, Weijie
Qi, Lihong
Mahavongtrakul, Angelique
Li, Ying
Li, Hong
Gong, Jay
Fan, Reggie R.
Li, Jin
Molmen, Michael
Clark, Travis A.
Pavlick, Dean
Frampton, Garrett M.
Forcier, Brady
Moore, Elizabeth H.
Shelton, David K.
Cooke, Matthew
Ali, Siraj M.
Miller, Vincent A.
Gregg, Jeffrey P.
Stephens, Philip J.
Li, Tianhong
-
Funding
Funding for this research was provided by:
FMI-CTDNA-15
Personalized Cancer Therapy Gift Fund
- License Information
-
More Information
Article History
Received: 4 September 2018
Accepted: 11 October 2018
First Online: 6 November 2018
Ethics approval and consent to participate
: The study was approved by the institutional review board (IRB) at the University of California, Davis (IRB ID: 937274).
: Not applicable
: Jeffrey P. Gregg: Foundation Medicine (H), AstraZeneca (H), AstraZeneca (SAB), and BMS (C/A). Tianhong Li: NCI (RF), Pfizer (RF), Foundation Medicine (C/A), Takada (C/A), and Puma (C/A). Michael Molmen: Foundation Medicine (E, OI); Travis A. Clark: Foundation Medicine (E, OI); Dean Pavlick: Foundation Medicine (E, OI); Brady Forcier: Foundation Medicine (E, OI); Garret M. Frampton: Foundation Medicine (E, OI, IP); Matthew Cooke Foundation Medicine (E, OI); Siraj M. Ali Foundation Medicine (E, OI); Vincent A. Miller: Foundation Medicine (E, OI); Philip J. Stephens: Foundation Medicine (E, OI, IP).(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/ inventor/patent holder; (SAB) Scientific advisory board.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
